Previous 10 | Next 10 |
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today is pleased to release to sha...
MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the ...
Gainers: Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
Immuron (NASDAQ: IMRN ) has priced its public offering of 339,130 ADSs, at $4.00 per share, for gross proceeds of ~$1,356,520. Each ADS represents 40 ordinary shares of the Company. More news on: Immuron Limited, Healthcare stocks news, Stocks on the move, Read more ...
Xenetic Biosciences (NASDAQ: XBIO ) -47% on pricing $15M public offering. More news on: Xenetic Biosciences, Inc., Nu Skin Enterprises, Inc., Immuron Limited, Stocks on the move, Read more ...
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor webinar and Q&A session on Thursday, July 18, 2019, at 10:30 a.m. EST (US time), hosted by R...
Immuron (NASDAQ: IMRN ) +134% on revenue surge . More news on: Immuron Limited, Neovasc Inc., Bio-Path Holdings, Inc., Stocks on the move, Read more ...
Thinly traded nanoc cap Immuron Limited (NASDAQ: IMRN ) is up 137% premarket on increased volume in reaction to its fiscal 2019 results that included a 52% jump in North America sales to $1.16M. More news on: Immuron Limited, Healthcare stocks news, Earnings news and commentary...
Key Highlights: Immuron FY19 revenue surged by 52% in North America, reaching $1.16M. In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD. In May 2019, USA Travelan® sales achieved a record-breaking $182...
MELBOURNE, Australia, June 25, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter Anastasiou and Mr Daniel Pollock have recently acquired on-market 1,000,000 (25,000 ADS equivalent) ...
News, Short Squeeze, Breakout and More Instantly...
Immuron Limited Company Name:
IMRN Stock Symbol:
NASDAQ Market:
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated bio...
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other bu...
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated b...